Kontrol Altında ve Kontrol Altında Olmayan Tip 2 Diyabete SahipKronik Periodontitisli Bireylerde Tükürük, Serum ve GCF VisfatinSeviyelerinin İncelenmesi

Amaç: Bu çalışmanın amacı, metabolik kontrolleri iyi ve kötü diyabetikkronik periodontitisli hastaların ve non-diyabetik kronik periodontitislihastaların DOS, tükürük ve serum örneklerinde visfatin seviyelerininaraştırılmasıdır. Gereç ve Yöntemler: Bu çalışmada her biri 15 katılımcıdan oluşan 5grup oluşturuldu; sistemik sağlıklı ve periodontal olarak sağlıklıbireylerin oluşturduğu grup (DM-P-), sistemik sağlıklı ve kronikperiodontitisli grup (DM-P+), diyabetli ve periodontal olarak sağlıklıgrup (DM+P-) ile diyabetli ve kronik periodontitisli grup (DM+P+),kontrolsüz diyabetli ve kronik periodontitisli grup (uDM+P+). Serum,tükürük ve DOS örneklerinin alınmasını takiben klinik periodontalparametreler kaydedildi. Lokal ve sistemik visfatin, TNF-α ve IL-1β düzeyleri biyokimyasal olarak ölçüldü. Bulgular: En yüksek visfatin, TNF-α ve IL-1β seviyeleri (uDM+P+)grubunda tespit edildi (p>0.001). (uDM+P+) grubunda DOS visfatinseviyeleri ile DOS TNF-α ve DOS IL-1β seviyeleri arasında istatistikselolarak anlamlı pozitif korelasyonlar tespit edildi (p

Evaluation of Serum, Saliva and GCF Visfatin Levels in Chronic Periodontitis Patientswith Uncontrolled /Controlled Type2 Diabetes Mellitus

Background: The aim of this study is to investigate visfatinlevels in serum, saliva and GCF samples of non-diabetic CPpatients, CP patients with t2DM and ut2DM, and to evaluateof the relationship with clinical and biochemical parameters ofCP. Methods: Study protocol, 5 groups which each one wereconsisted of 15 subjects were planned: patients with bothperiodontal and systemic health (DM-P-); CP patients withsystemic health (DM-P+), periodontally healthy patients withdiabetes (DM+P-), patients with diabetes and CP (DM+P+),patients with uncontrolled diabetes and CP (uDM+P+).Serum, saliva and GCF samples were collected and levels ofvisfatin, TNF-α and IL-1β were determined by ELISA. Results: The highest levels of visfatin, TNF-α and IL-1β wereseen in (uDM+P+) group (p>0.001). Significant positivecorrelations between GCF visfatin levels and GCF TNF-α andIL-1β levels were detected in (uDM+P+) group (p

PDF

___

1. Lang, N. P., Schätzle, M. A., & Löe, H. (2009). Gingivitis as a risk factor in periodontal disease. Journal of clinical periodontology, 36, 3-8.
2. Buduneli, N. (2021). Environmental factors and periodontal microbiome. Periodontology 2000, 85(1), 112-125.
3. Genco, R. J., Graziani, F., & Hasturk, H. (2020). Effects of periodontal disease on glycemic control, complications, and incidence of diabetes mellitus. Periodontology 2000, 83(1), 59-65.
4. Gabir, M. M., Hanson, R. L., Dabelea, D., Imperatore, G., Roumain, J., Bennett, P. H., & Knowler, W. C. (2000). The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes care, 23(8), 1108-1112.
5. Löe, H. (1993). Periodontal disease: the sixth complication of diabetes mellitus. Diabetes care, 16(1), 329-334.
6. Grossi, S. G., & Genco, R. J. (1998). Periodontal disease and diabetes mellitus: a two‐way relationship. Annals of periodontology, 3(1), 51-61.
7. Fukuhara, A., Matsuda, M., Nishizawa, M., Segawa, K., Tanaka, M., Kishimoto, K., ... & Shimomura, I. (2005). Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science, 307(5708), 426-430.
8. Ognjanovic, S., Bao, S., Yamamoto, S. Y., GaribayTupas, J., Samal, B., & Bryant-Greenwood, G. D. (2001). Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes. Journal of molecular endocrinology, 26(2), 107-118.
9. Moschen, A. R., Kaser, A., Enrich, B., Mosheimer, B., Theurl, M., Niederegger, H., & Tilg, H. (2007). Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. The Journal of Immunology, 178(3), 1748-1758.
10.Hammarstedt, A., Pihlajamäki, J., Rotter Sopasakis, V., Gogg, S., Jansson, P. A., Laakso, M., & Smith, U. (2006). Visfatin is an adipokine, but it is not regulated by thiazolidinediones. The Journal of Clinical Endocrinology & Metabolism, 91(3), 1181-1184.
11.Pradeep, A. R., Raghavendra, N. M., Prasad, M. R., Kathariya, R., Patel, S. P., & Sharma, A. (2011). Gingival crevicular fluid and serum visfatin concentration: their relationship in periodontal health and disease. Journal of periodontology, 82(9), 1314- 1319.
12.Heo, Y. J., Choi, S. E., Jeon, J. Y., Han, S. J., Kim, D. J., Kang, Y., ... & Kim, H. J. (2019). Visfatin induces inflammation and insulin resistance via the NF-κB and STAT3 signaling pathways in hepatocytes. Journal of diabetes research, 2019.
13.Armitage, G. C. (1999). Development of a classification system for periodontal diseases and conditions. Annals of periodontology, 4(1), 1-6.
14.Care, D. (2010). Executive summary: standards of medical care in diabetes—2010. Diabetes Care, 33(supplement 1), S4-S10.
15.Leong, K. S., & Wilding, J. P. (1999). Obesity and diabetes. Best Practice & Research Clinical Endocrinology & Metabolism, 13(2), 221-237.
16.Nourbakhsh, M., Nourbakhsh, M., Gholinejad, Z., & Razzaghy-Azar, M. (2015). Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome. Scandinavian Journal of Clinical and Laboratory Investigation, 75(2), 183-188.
17.Pradeep, A. R., Raghavendra, N. M., Sharma, A., Patel, S. P., Raju, A., Kathariya, R., ... & Naik, S. B. (2012). Association of serum and crevicular visfatin levels in periodontal health and disease with type 2 diabetes mellitus. Journal of periodontology, 83(5), 629-634.
18.Bahammam, M. A., & Attia, M. S. (2018). Effects of systemic simvastatin on the concentrations of visfatin, tumor necrosis factor-α, and interleukin-6 in gingival crevicular fluid in patients with type 2 diabetes and chronic periodontitis. Journal of immunology research, 2018.
19.McGlothlin, J. R., Gao, L., Lavoie, T., Simon, B. A., Easley, R. B., Ma, S. F., ... & Ye, S. Q. (2005). Molecular cloning and characterization of canine pre-Bcell colony-enhancing factor. Biochemical genetics, 43(3-4), 127-141.
20.Nishimura, F., Iwamoto, Y., Mineshiba, J., Shimizu, A., Soga, Y., & Murayama, Y. (2003). Periodontal disease and diabetes mellitus: the role of tumor necrosis factor‐ α in a 2‐way relationship. Journal of periodontology, 74(1), 97-102.
21.Graves, D. T., & Cochran, D. (2003). The contribution of interleukin‐1 and tumor necrosis factor to periodontal tissue destruction. Journal of periodontology, 74(3), 391-401.
22.Saseendran, G., Abraham, S., Nair, A. M., & Reejamol, M. K. (2021). Comparative evaluation of salivary visfatin levels in healthy and periodontally diseased patients before and after scaling and root planing. Journal of Pharmacy and Bioallied Sciences, 13(5), 624.
23.Raghavendra, N. M., Pradeep, A. R., Kathariya, R., Sharma, A., Rao, N. S., & Naik, S. B. (2012). Effect of non-surgical periodontal therapy on gingival crevicular fluid and serum visfatin concentration in periodontal health and disease. Disease markers, 32(6), 383-388.
24.Wu, Y., Chen, L., Wei, B., Luo, K., & Yan, F. (2015). Effect of non‐surgical periodontal treatment on visfatin concentrations in serum and gingival crevicular fluid of patients with chronic periodontitis and type 2 diabetes mellitus. Journal of periodontology, 86(6), 795-800.
25.El-Shaer, O. S., Belal, K. M., & Hesham, A. I. (2012). Increased serum visfatin levels in patients with type 2 diabetic patients. Life Science Journal, 93.